机译:主要骨科手术患者围手术期输血后的死亡率,发病率和相关结果:系统审查
Division Safety of Medicinal Products and Medical Devices Paul-Ehrlich-Institut Langen Germany;
Division Safety of Medicinal Products and Medical Devices Paul-Ehrlich-Institut Langen Germany;
Division Safety of Medicinal Products and Medical Devices Paul-Ehrlich-Institut Langen Germany;
Division Safety of Medicinal Products and Medical Devices Paul-Ehrlich-Institut Langen Germany;
Division Safety of Medicinal Products and Medical Devices Paul-Ehrlich-Institut Langen Germany;
Division Safety of Medicinal Products and Medical Devices Paul-Ehrlich-Institut Langen Germany;
Erythrocyte transfusion; Haemovigilance; Immunomodulation; Non-haemolytic transfusion reactions; Peri-operative period; Restrictive and liberal transfusion regimes; Systematic review; Meta-analyses;
机译:主要骨科手术患者围手术期输血后的死亡率,发病率和相关结果:系统审查
机译:Sandini M,Pinotti E,Persico I,Picone D,Bellelli G,Gianotti L.系统评价和Meta分析作为发病率和死亡率的预测因素,在主要的腹部外科系统审查和荟萃分析的情况下 主要腹部手术后的发病率和死亡率的预测因素.BJS开放。 2017; 1(5):128-137
机译:围手术期输血和胆管癌手术患者的临床结局:系统评价和荟萃分析
机译:接受主要手术患者的围手术期疼痛管理
机译:制定和确认输血风险:了解评分工具(TRUST),根据心脏手术患者的输血需求对其进行分层。
机译:骨科大手术患者围手术期输血后的死亡率发病率及相关结果:系统评价
机译:主要骨科手术患者围手术期输血后的死亡率,发病率和相关结果:系统审查